Erratum: Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma (Clinical Kidney Journal (2016) 9 (411-417) DOI: 10.1093/ckj/sfw024);Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Clinical Kidney Journal

Volumn 9, Issue 3, 2016, Pages 411-417

  Murakami, Naoka ^a   Borges, Thiago J ^a   Yamashita, Michifumi ^a   Riella, Leonardo V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute kidney injury; Immune checkpoint blockade; Interstitial nephritis

Indexed keywords

ALBUMIN; CD4 ANTIGEN; CD8 ANTIGEN; CIPROFLOXACIN; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; IPILIMUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PERFORIN; PREDNISONE; SULFANILAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMEN; ACUTE KIDNEY FAILURE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACK; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE BLOOD LEVEL; CUTANEOUS MELANOMA; DERMATITIS; DRUG DOSE INCREASE; ESSENTIAL HYPERTENSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LEG EDEMA; LOCAL EXCISION; LYMPH NODE METASTASIS; MALE; MEASLES LIKE RASH; METASTATIC MELANOMA; NASOLABIAL FOLD; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; STEROID THERAPY; SUBMANDIBULAR LYMPH NODE; THORAX; URINALYSIS; WEIGHT REDUCTION;

EID: 84978986900     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw058     Document Type: Erratum

References (26)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
3. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028
4. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813
5. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697
6. Murakami N, Riella LV. Co-inhibitory pathways and their importance in immune regulation. Transplantation 2014; 98: 3-14
7. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60
8. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
9. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289
10. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211-212
11. Forde PM, Rock K, Wilson G et al. Ipilimumab-induced immune-related renal failure-a case report. Anticancer Res 2012; 32: 4607-4608
12. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745
13. Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014; 32: 769-773
14. Thajudeen B, Madhrira M, Bracamonte E et al. Ipilimumab granulomatous interstitial nephritis. Am J Ther 2015; 22: e84-e87
15. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-988
16. Tivol EA, Borriello F, Schweitzer AN et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547
17. Kuehn HS, Ouyang W, Lo B et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014; 345: 1623-1627
18. Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014; 20: 1410-1416
19. Ise W, Kohyama M, Nutsch KM et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010; 11: 129-135
20. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151
21. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322
22. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532
23. Das R, Verma R, SznolMet al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194: 950-959
24. Malhotra D, Linehan JL, Dileepan T et al. Tolerance is established in polyclonal CD4T cells by distinct mechanisms, according to self-peptide expression patterns. Nat Immunol 2016; 17: 187-195
25. KuchrooVK,OhashiPS,SartorRBet al. Dysregulation ofimmune homeostasis in autoimmune diseases. NatMed 2012; 18: 42-47
26. Horvat TZ, Adel NG, Dang TO et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193-3198